BioCentury
ARTICLE | Product Development

CAR window

How MaxCyte, JHU Kimmel Cancer Center plan to develop safer CARs for solid tumors

April 27, 2015 7:00 AM UTC

MaxCyte Inc. is collaborating with the Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University to develop transiently expressed chimeric antigen receptor T cell therapies that may allow better control over the cells' therapeutic window. MaxCyte hopes the approach will enable the therapies to safely target antigens expressed on solid tumors.

Under a deal announced Tuesday, MaxCyte and the center will collaborate on preclinical development of CAR T cell therapies directed against solid tumor targets, starting with mesothelin. Other targets, as well as financial terms, are undisclosed...